<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551122</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000572096</org_study_id>
    <secondary_id>USCTU-UR1002-GEM-TIP</secondary_id>
    <secondary_id>EU-20769</secondary_id>
    <secondary_id>EUDRACT-2004-004804-19</secondary_id>
    <nct_id>NCT00551122</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors</brief_title>
  <acronym>GemTIP</acronym>
  <official_title>Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and&#xD;
      cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when&#xD;
      given together with paclitaxel, ifosfamide, and cisplatin, and to see how well they work in&#xD;
      treating patients with progressive or relapsed metastatic germ cell tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of gemcitabine hydrochloride when&#xD;
           administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with&#xD;
           growth factor support (Gem-TIP) in patients with progressive or relapsed metastatic germ&#xD;
           cell tumors.&#xD;
&#xD;
        -  To compare the MTD of the Gem-TIP regimen with the MTD determined in a previous Medical&#xD;
           Research Council study of TIP alone.&#xD;
&#xD;
        -  To compare the degree of dose intensification achieved with Gem-TIP chemotherapy with&#xD;
           that achieved in the prior study of TIP chemotherapy alone.&#xD;
&#xD;
        -  To assess the dose of gemcitabine hydrochloride that can be delivered with the TIP&#xD;
           regimen in these patients.&#xD;
&#xD;
        -  To measure response rates and failure-free survival of patients treated with Gem-TIP&#xD;
           alone.&#xD;
&#xD;
        -  To assess the utility of PET scanning after Gem-TIP chemotherapy in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of gemcitabine hydrochloride&#xD;
      followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes and paclitaxel IV&#xD;
           over 3 hours on day 1, cisplatin IV over 4 hours on days 1-5, and ifosfamide IV over 1&#xD;
           hour on days 2-6. Patients also receive filgrastim or lenograstim (G-CSF) subcutaneously&#xD;
           (SC) on days 7-18 or until blood counts recover OR pegfilgrastim SC once on day 6.&#xD;
           Treatment repeats every 3 weeks for up to 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Phase II: An additional cohort of 14 patients is treated as in phase I at the MTD&#xD;
           determined in phase I.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 1 year and&#xD;
      then at the investigator's discretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure-free survival (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.&#xD;
If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.&#xD;
Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.&#xD;
MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lenograstim</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets the following criteria:&#xD;
&#xD;
               -  Histologically confirmed extracranial primary germ cell cancer, seminoma, or&#xD;
                  nonseminoma&#xD;
&#xD;
                    -  Unresectable metastatic disease&#xD;
&#xD;
                    -  No completely resected cancer&#xD;
&#xD;
               -  Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin)&#xD;
                  on sequential measurement or biopsy-proven unresectable germ cell cancer&#xD;
&#xD;
          -  In first relapse after a single prior cisplatin-containing combination chemotherapy&#xD;
&#xD;
               -  Patients with late relapse (i.e., &gt; 2 years post initial chemotherapy) should be&#xD;
                  considered for surgery rather than chemotherapy, if technically feasible&#xD;
&#xD;
          -  No patients with cerebral metastases alone&#xD;
&#xD;
               -  Progressive cerebral and systemic disease may be considered for this study,&#xD;
                  provided cranial irradiation is also considered as a component of care&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Medically and psychologically fit to receive this intensive chemotherapy schedule&#xD;
&#xD;
          -  WBC &gt; 3.5 times 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 130 times 10^9/L&#xD;
&#xD;
          -  Glomerular filtration rate â‰¥ 50 mL/min (as determined by 24 hour creatinine clearance&#xD;
             or nuclear medicine technique)&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy except successfully treated nonmelanoma skin cancer or&#xD;
             superficial bladder cancer&#xD;
&#xD;
          -  No prior allergic reactions to cisplatin or other platinum compounds&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Mead, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael H. Cullen, MD</last_name>
      <phone>0121-627-2444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Mead, MD</last_name>
      <phone>44-23-8079-8639</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A. Huddart, MD</last_name>
      <phone>44-20-8661-3457</phone>
      <email>robert.huddart@icr.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>testicular seminoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>recurrent extragonadal seminoma</keyword>
  <keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage IV extragonadal seminoma</keyword>
  <keyword>recurrent extragonadal germ cell tumor</keyword>
  <keyword>ovarian mixed germ cell tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

